Clinical Trial

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-19; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2024-06-24
Trial Details
NCT Number NCT06099093
Lead Sponsor Brigham and Women's Hospital
Collaborators: Progenics Pharmaceuticals, Inc.
Conditions Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
Enrollment 30 participants
Start Date 2024-04-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-29